RTL5

Model summary

A soluble human regulatory scaffold that assembles higher-order complexes through tandem capsid-like modules to modulate gene expression. By building multivalent protein-binding assemblies in the cytoplasm and transiently entering the nucleus, it likely sequesters and recruits transcriptional regulators to dampen RNA polymerase II–driven transcription. Its mechanism centers on oligomerization that stabilizes repressor complexes and coordinates their cytosolic assembly with nucleoplasmic action.

Predicted Gene Ontology terms

1. 01

   I begin with the InterPro architecture.

   The central body of the protein is defined by IPR032567 (RTL1/3-8/LDOC-like family, residues 125–475), which frames the overall identity as an RTL1/LDOC-like regulator. Within this scaffold sit two capsid-like modules arranged in tandem: IPR032549 (RTL1/3-8/LDOC, capsid-like domain, residues 153–228) followed by IPR063300 (PEG10/RTL1, C-terminal capsid-like domain, residues 237–310). Capsid-like folds are non-enzymatic oligomerization platforms that assemble higher-order complexes and frequently mediate selective macromolecular binding. Their placement in the mid-to-C-terminal region creates a bipartite assembly core that nucleates multimeric complexes and provides avidity for diverse partners. This architecture causally supports a molecular role dominated by multivalent protein association rather than catalysis, aligning with GO:0005515 protein binding as the primary molecular function.

2. 02

   From this binding-centric core, I infer regulatory outcomes.

   RTL/LDOC-like families often tune transcription indirectly by forming oligomeric hubs that recruit or sequester transcriptional regulators. The tandem capsid-like domains provide a structural basis for assembling repressor complexes that dampen RNA polymerase II output, consistent with GO:0000122 negative regulation of transcription by RNA polymerase II. Such repression can arise either by stabilizing corepressor assemblies or by spatially segregating transcription factors away from chromatin.

3. 03

   Cellular localization follows from the same assembly logic.

   The absence of transmembrane segments and the presence of soluble oligomerization domains argue for a cytosolic pool, matching GO:0005829 cytosol and the broader cytoplasmic designation. The need to modulate transcription necessitates transient nuclear access; oligomerization-driven shuttling of regulatory complexes explains a nucleoplasmic fraction (GO:0005654 nucleoplasm). Thus, the protein operates as a soluble scaffold that cycles between cytosol and nucleoplasm to exert transcriptional control.

4. 04

   Mechanistically, I hypothesize that the capsid-like tandem domains drive formation of higher-order assemblies that titrate transcriptional regulators and chromatin-modifying enzymes.

   In the cytosol, these assemblies can sequester co-repressors and RNA-binding factors; upon nuclear entry, they stabilize repressor complexes at target loci to reduce RNA polymerase II activity. Likely interaction partners include transcriptional corepressors and chromatin remodelers that recognize multivalent scaffolds, as well as RNA-binding proteins that tune mRNA maturation and export. Together, this soluble oligomerization platform provides a tunable node that links cytoplasmic complex assembly to nucleoplasmic repression of gene expression.